

REMARKS

No new matter is added by the amendments of the specification and claim 1 or by new claims 14-35.

The text at page 7, lines 21-22 of the specification has been rewritten in more appropriate grammatical form and claim 1 has been amended to put it in appropriate U.S. claim format.

Amended claim 1 and new claims 14-16 correspond to original claim 1 in which neither of, one of, or both of the optional elements are recited. Likewise, new claims 17-19 and 20-23 correspond to original claims 2 and 3 respectively.

New claims 24, 25 and 28-30 correspond to original claims 4, 5 and 8-10 respectively but depend only from the immediately preceding claim rather than from all preceding claims.

New claims 26 and 27 correspond to original claims 6 and 7 respectively.

New claim 31 corresponds to original independent claim 11 written in dependent form.

Original use claim 12, which depended from all preceding claims, has been replaced by new claims 32 and 33, which depend from claims 1 and 31 respectively.


Likewise, original use claim 13, which depended from claims 1-11, has been replaced by new claims 34 and 35, which depend from claim 1 and 31 respectively.

The application as presently amended contains claims 1 and 14-35.

Date:

25 July 00

Respectfully submitted,


Paul E. Dupont
Reg. No. 27,438

Address
Patent Department
Sanofi-Synthelabo Inc.
9 Great Valley Parkway
Malvern, PA 19355
Telephone No. (610) 889-6338
Facsimile: (610) 889-8799

005270" 89600960